Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva
研究概览
简要总结
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
详细描述
The objective of this proposed study is to determine the expression levels of a panel of markers including CD133, CD44, ABCC3, TNFRSF1A, AKT1, IDH2, and MGMT in GBM tissues and the CSF, blood, and saliva from patients with GBM receiving different types of treatment (Optune only or Optune with TMZ) and the non-brain tumor patients (controls). Our aims are: 1) To compare the differences of CD44 between the control group and the combined cancer groups at baseline; and 2) To compare the levels of CD44 and other markers among the 3 different groups such as control vs. GBM patients and Optune vs. Optune + TMZ after 8 weeks of treatment. Exploratory analysis of all other markers will be performed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •22 years old
- •Control Group (only patients evaluated for neurological disorders whose evaluation require a lumbar puncture)
- •Non-Control Group - Diagnosed with GBM (Glioblastoma)
排除标准
- •Pregnancy
- •Infectious Disease to include cold, flu, HIV, etc.
- •Blood Disorder (example:low platelets, anemia, thrombosis)
- •Vascular Malformations
结局指标
主要结局
Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva
时间窗: 2 years
Currently, Glioblastoma is only diagnosed and monitored with brain scans. Expression levels of CD44 along with CD133, ABCC3, TNFRSF1A, AKT1, IDH2 and MGMT in samples of CSF, blood and saliva from patients receiving different types of treatment and comparing them with non-GBM patients (control group) will be tested.
次要结局
未报告次要终点